Biohaven Pharmaceutical Holding Company Ltd

Biohaven Pharmaceutical Holding Company Ltd

  • Price (EUR)158.00
  • Today's Change0.00 / 0.00%
  • Shares traded8.00
  • 1 Year change+39.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 27 2022 16:15 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

  • Revenue in USD (TTM)859.68m
  • Net income in USD-1.02bn
  • Incorporated2013
  • Employees928.00
  • Location
    Biohaven Pharmaceutical Holding Company Ltd215 Church StNEW HAVEN 06510-1803United StatesUSA
  • Phone+1 (203) 404-0410
  • Websitehttps://www.biohavenpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BHVN:NYQ since
Channel Biosciences LLCDeal completed25 Feb 202225 Feb 2022Deal completed13.64%1.24bn
Data delayed at least 15 minutes, as of Sep 27 2022 16:29 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.